dimethylenastron and monastrol

dimethylenastron has been researched along with monastrol* in 2 studies

Other Studies

2 other study(ies) available for dimethylenastron and monastrol

ArticleYear
New chemical tools for investigating human mitotic kinesin Eg5.
    Bioorganic & medicinal chemistry, 2007, Oct-01, Volume: 15, Issue:19

    We have designed and synthesized a series of monastrol derivatives, an allosteric inhibitor of Eg5, a motor protein responsible for the formation and maintenance of the bipolar spindle in mitotic cells. Sterically demanding structural modifications have been introduced on the skeleton of the parent drug either via a multicomponent Biginelli reaction or a stepwise modification of monastrol. The ability of these compounds to inhibit Eg5 activity has been investigated using two in vitro steady-state ATPase assays (basal and microtubule-stimulated) as well as a cell-based assay. One compound in the series appeared more potent than monastrol by a fivefold factor. Three other compounds that were unable to inhibit Eg5 ATPase activity in vitro proved potent Eg5 inhibitors in the cell-based assay. The results obtained led to the identification of structure-activity relationships further used to design an affinity matrix that can be used for fast and efficient purification of Eg5 from crude lysate of eukaryotic cells.

    Topics: Antimitotic Agents; Biological Assay; Cells, Cultured; Drug Design; Enzyme Inhibitors; Eukaryotic Cells; Humans; Kinesins; Microtubules; Mitosis; Pyrimidines; Structure-Activity Relationship; Thiones

2007
Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    The inhibition of kinesin Eg5 by small molecules such as monastrol is currently evaluated as an approach to develop a novel class of antiproliferative drugs for the treatment of malignant tumours. Therefore, we studied the effects of the new monastrol analogues enastron, dimethylenastron and vasastrol VS-83 on the proliferation of human glioblastoma cells in the kinetic crystal violet assay. Compared to monastrol, the new cell cycle specific compounds showed an at least one order of magnitude higher anti proliferative activity against U-87 MG, U-118 MG, and U-373 MG glioblastoma cells. The compounds were neither inactivated by hydrolysis nor by binding to serum proteins. Moreover, we demonstrated the characteristic monoaster formation after incubation of cells with the new compounds by confocal laser scanning microscopy. We also showed that the arrangement of beta-actin and tubulin, vital components of the cyto-skeleton of mitotic and quiescent cells, were not affected by the new compounds. Due to the necessity of overcoming the blood-brain barrier in the treatment of brain tumours, we investigated if the new monastrol analogues are modulators or substrates of the p-glycoprotein (p-gp) 170 by a flow cytometric calcein-AM efflux assay. The tested compounds showed no modulating effects on the p-gp function. With respect to the treatment of primary and secondary CNS tumours, the results of our experiments suggest that the new monastrol analogues represent an interesting class of potential anticancer drugs, predicted to be less neurotoxic in comparison to classical tubulin inhibitors.

    Topics: Acridines; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cysteine; Dose-Response Relationship, Drug; Flow Cytometry; Fluoresceins; Glioblastoma; Humans; Insecticides; Kinesins; Molecular Structure; Paclitaxel; Pyrimidines; Quinazolines; Rotenone; Spindle Apparatus; Tetrahydroisoquinolines; Thiones; Time Factors; Tubulin; Tubulin Modulators; Vinblastine

2007